48 related articles for article (PubMed ID: 26749158)
1. Factors associated with non-adherence to Buprenorphine-naloxone among opioid dependent African-Americans: A retrospective chart review.
Kumari S; Manalai P; Leong S; Wooditch A; Malik M; Lawson WB
Am J Addict; 2016 Mar; 25(2):110-7. PubMed ID: 26749158
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of buprenorphine (naloxone) for opioid dependence does not differ across opioid categories: a retrospective cohort study from India.
Ghosh A; Shaktan A; Basu D; Bn S; Naik SS; Mattoo SK
J Psychoactive Drugs; 2024; 56(3):364-372. PubMed ID: 37318513
[TBL] [Abstract][Full Text] [Related]
3. Investigation of Simulated Adherence in Long-Term Buprenorphine/Naloxone Treatment Patients.
Rahman N; Janardhanan A; Shikalgar S; Pirkhan MA; Canner J; Skipwith C; Noor-E-Alam M
Subst Use Misuse; 2024; 59(9):1275-1279. PubMed ID: 37950394
[TBL] [Abstract][Full Text] [Related]
4. Treatment outcomes in opioid dependent patients with different buprenorphine/naloxone induction dosing patterns and trajectories.
Jacobs P; Ang A; Hillhouse MP; Saxon AJ; Nielsen S; Wakim PG; Mai BE; Mooney LJ; S Potter J; Blaine JD
Am J Addict; 2015 Oct; 24(7):667-75. PubMed ID: 26400835
[TBL] [Abstract][Full Text] [Related]
5. The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone.
Sullivan LE; Botsko M; Cunningham CO; O'Connor PG; Hersh D; Mitty J; Lum PJ; Schottenfeld RS; Fiellin DA;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S54-61. PubMed ID: 21317595
[TBL] [Abstract][Full Text] [Related]
6. Development of an integrated digital health intervention to promote engagement in and adherence to medication for opioid use disorder.
Langdon KJ; Ramsey S; Scherzer C; Carey K; Ranney ML; Rich J
Addict Sci Clin Pract; 2020 Apr; 15(1):16. PubMed ID: 32349790
[TBL] [Abstract][Full Text] [Related]
7. Using behavioral economics to predict opioid use during prescription opioid dependence treatment.
Worley MJ; Shoptaw SJ; Bickel WK; Ling W
Drug Alcohol Depend; 2015 Mar; 148():62-8. PubMed ID: 25622776
[TBL] [Abstract][Full Text] [Related]
8. Harm Reduction Approach to Increasing Self-reported Safe Medication Storage Among Pregnant and Parenting People Receiving Opioid Use Disorder Treatment.
Grist E; Thakkar B; Dacha P; Lutins E; Maxwell M; Martin CE
J Addict Med; 2023 Mar-Apr 01; 17(2):215-218. PubMed ID: 36730907
[TBL] [Abstract][Full Text] [Related]
9. Use of urinary naloxone levels in a single provider practice: a case study.
Warrington JS; Booth K; Warrington GS; Francis-Fath S
Addict Sci Clin Pract; 2020 Jan; 15(1):3. PubMed ID: 31941557
[TBL] [Abstract][Full Text] [Related]
10. Correlates of Opioid Abstinence in a 42-Month Posttreatment Naturalistic Follow-Up Study of Prescription Opioid Dependence.
Weiss RD; Griffin ML; Marcovitz DE; Hilton BT; Fitzmaurice GM; McHugh RK; Carroll KM
J Clin Psychiatry; 2019 Mar; 80(2):. PubMed ID: 30920187
[TBL] [Abstract][Full Text] [Related]
11. Associations Between Buprenorphine\Naloxone and Methadone Treatment and non-Opioid Substance Use in Prescription-Type Opioid Use Disorder: Secondary Analyses From the OPTIMA Study: Associations entre le traitement avec la buprénorphine/naloxone et avec la méthadone et l'utilisation de substances non opioïdes dans le trouble lié à l'usage d'opioïdes de type sur ordonnance : analyses secondaires de l'étude OPTIMA.
Bakouni H; Sharafi H; Drouin S; Fortin R; Marsan S; Brissette S; Socias ME; Le Foll B; Lim R; Jutras-Aswad D
Can J Psychiatry; 2024 Apr; 69(4):252-263. PubMed ID: 37899716
[TBL] [Abstract][Full Text] [Related]
12. Counseling and directly observed medication for primary care buprenorphine maintenance: a pilot study.
Moore BA; Barry DT; Sullivan LE; Oʼconnor PG; Cutter CJ; Schottenfeld RS; Fiellin DA
J Addict Med; 2012 Sep; 6(3):205-11. PubMed ID: 22614936
[TBL] [Abstract][Full Text] [Related]
13. Homelessness and Treatment Outcomes Among Black Adults With Opioid Use Disorder: A Secondary Analysis of X:BOT.
Justen M; Scodes J; Pavlicova M; Choo TH; Gopaldas M; Haeny A; Opara O; Rhee TG; Rotrosen J; Nunes EV; Hawk K; Edelman EJ
J Addict Med; 2023 Jul-Aug 01; 17(4):463-467. PubMed ID: 37579110
[TBL] [Abstract][Full Text] [Related]
14. Drug test results as a predictor of retention among patients using buprenorphine in a comprehensive outpatient treatment program.
Campbell MD; Kolodner G; Spencer RA; DuPont RL
J Addict Dis; 2016; 35(4):315-324. PubMed ID: 26757093
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with non-adherence and misuse of opioid maintenance treatment medications and intoxicating drugs among Finnish maintenance treatment patients.
Launonen E; Wallace I; Kotovirta E; Alho H; Simojoki K
Drug Alcohol Depend; 2016 May; 162():227-35. PubMed ID: 27068849
[TBL] [Abstract][Full Text] [Related]
16. Differentiating the Effect of an Opioid Agonist on Cardiac Repolarization From µ-Receptor-mediated, Indirect Effects on the QT Interval: A Randomized, 3-way Crossover Study in Healthy Subjects.
Darpo B; Zhou M; Bai SA; Ferber G; Xiang Q; Finn A
Clin Ther; 2016 Feb; 38(2):315-26. PubMed ID: 26749217
[TBL] [Abstract][Full Text] [Related]
17. Patient Feedback on a Mobile Medication Adherence App for Buprenorphine and Naloxone: Closed and Open-Ended Survey on Feasibility and Acceptability.
Smith CL; Keever A; Bowden T; Olson K; Rodin N; McDonell MG; Roll JM; Smoody G; LeBrun J; Miguel AQ; McPherson SM
JMIR Form Res; 2023 Apr; 7():e40437. PubMed ID: 37074780
[TBL] [Abstract][Full Text] [Related]
18. Use of a sequential multiple assignment randomized trial to test contingency management and an integrated behavioral economic and mindfulness intervention for buprenorphine-naloxone medication adherence for opioid use disorder.
Peter SC; Murphy JG; Witkiewitz K; Hand SB; Thomas F; Johnson KC; Cowan R; Harris M; Derefinko KJ
Trials; 2023 Mar; 24(1):237. PubMed ID: 36991453
[TBL] [Abstract][Full Text] [Related]
19. An Evaluation of Opioid Use in Black Communities: A Rapid Review of the Literature.
Jordan A; Mathis M; Haeny A; Funaro M; Paltin D; Ransome Y
Harv Rev Psychiatry; 2021 Mar-Apr 01; 29(2):108-130. PubMed ID: 33666395
[TBL] [Abstract][Full Text] [Related]
20. Extended-release naltrexone versus buprenorphine-naloxone to treat opioid use disorder among black adults.
Haeny AM; Montgomery L; Burlew AK; Campbell ANC; Scodes J; Pavlicova M; Rotrosen J; Nunes E
Addict Behav; 2020 Nov; 110():106514. PubMed ID: 32619868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
